Multi-gene test predicts Alzheimer's better than APOE E4 alone

September 22, 2017 by Laura Kurtzman, University of California, San Francisco
PET scan of a human brain with Alzheimer's disease. Credit: public domain

A new test that combines the effects of more than two dozen genetic variants, most associated by themselves with only a small risk of Alzheimer's disease, does a better job of predicting which cognitively normal older adults will go on to develop Alzheimer's dementia than testing only for the well-known genetic variant APOE E4, a scientific team led by researchers at UC San Francisco and UC San Diego has found.

APOE E4 has long been considered the strongest genetic predictor of whether someone is likely to develop Alzheimer's, although it is only carried by 10 to 15 percent of the population and recent research suggests its effects have been overstated. The polygenic hazard score (PHS), a test developed by the research team that carried out the new study, provides risk estimates for the remaining 85 to 90 percent of people who do not carry at least one copy of APOE E4 but still have some combination of other genetic variants that put them at risk of Alzheimer's.

"Beyond APOE E4 by itself, our polygenic hazard score can identify cognitively normal and mildly impaired older folks who are at greatest risk for developing Alzheimer's-associated clinical decline over time," said Chin Hong Tan, PhD, a postdoctoral scholar at UCSF and first author of the paper, published Sept. 22, 2017, in Annals of Neurology.

The researchers looked at five years of data on 1,081 subjects from the National Alzheimer's Coordinating Center (NACC) who did not have dementia, and found the PHS test could predict how long it would take for them to progress to Alzheimer's dementia, as well as how steep their cognitive decline would be, even after taking into account whether they were carriers of APOE E4.

Autopsies of those who did develop Alzheimer's showed that, even among those who did not carry a copy of the APOE E4 variant, a higher PHS was associated with a higher level of amyloid plaque - a protein aggregate that is a hallmark of Alzheimer's—in the brain. These patients also showed steeper declines on cognitive tests during their lifetimes. Older individuals in the highest PHS percentiles also showed the highest incidence of Alzheimer's, which is diagnosed with cognitive tests and brain pathology, regardless of their APOE E4 status.

Many scientists now believe that rather than being a of aging, Alzheimer's may be the result of a disease process that begins years, perhaps decades, before symptoms of dementia appear. This is thought by many to be one reason why so many Alzheimer's drugs tested on older people with dementia have failed in clinical trials. The new PHS could help in the search for ways to identify those at risk of Alzheimer's long before they show symptoms of dementia, so they can be treated before the disease begins ravaging their brains, the researchers said.

"Our findings have strong implications for disease stratification and secondary prevention trials in Alzheimer's, as well as direct-to-consumer genetic tests, some of which have recently received FDA clearance," said Anders Dale, PhD, Professor of Neurosciences and Radiology at UC San Diego and co-author of the new study.

The PHS test enables researchers to calculate an age-specific risk of developing Alzheimer's, based upon each person's share of 31 genetic variants, plus APOE E4. The test makes its predictions by using genetic data from more than 70,000 people in the NACC database, the International Genomics of Alzheimer's Disease Project and the Alzheimer's Disease Genetics Consortium.

"Unlike other polygenic risk scores, the continuous PHS measure is based on a survival framework and incorporates US-based Alzheimer's incidence rates," said Rahul Desikan, MD, PhD, an assistant professor in the Department of Radiology and Biomedical Imaging at UCSF, and co-senior author of the paper. "Rather than a diagnostic , PHS may serve as a genetic 'risk factor' for preclinical Alzheimer's disease."

Explore further: Men, women and risk of developing Alzheimer disease: Is there a difference?

Related Stories

Men, women and risk of developing Alzheimer disease: Is there a difference?

August 28, 2017
Are female carriers of the apolipoprotein E ?4 allele, the main genetic risk factor for late-onset Alzheimer disease, at greater risk of developing the disease than men? A new article published by JAMA Neurology examines ...

New genetic risk marker for late-life depression

November 3, 2015
One of the most powerful predictors in neuropsychiatry is the epsilon 4 (ε4) allele of the apolipoprotein gene (APOE).

Genetic assessment developed to determine risk for age-associated Alzheimer's disease

March 21, 2017
An international team of scientists, led by researchers at University of California San Diego School of Medicine and University of California San Francisco, has developed a novel genetic score that allows individuals to calculate ...

Active lifestyle associated with less Alzheimer disease-related brain change among persons with APOE epsilon4 genotype

January 16, 2012
A sedentary lifestyle is associated with greater cerebral amyloid deposition, which is characteristic of Alzheimer’s disease (AD), among cognitively normal individuals with the ε4 allele of the apolipoprotein E ...

Impact of major Alzheimer's-related gene may be felt years before any symptoms appear

July 13, 2015
The best-known genetic variant linked to Alzheimer's disease may be "at work" promoting deposits of plaque in the brain long before any symptoms of the disease can be measured on tests, according to a national research study ...

Genetic risk factors for Alzheimer's disease may be detectable even in young adults

July 6, 2016
New research shows that a genetic risk score may detect those at higher risk for Alzheimer's disease long before symptoms appear—even possibly in healthy young adults, according to a study published in the July 6, 2016, ...

Recommended for you

A new way of thinking about tau kinetics, an essential component of Alzheimer's disease

March 21, 2018
Alzheimer's disease is most often characterized by two different pathologies in the brain: plaque deposits of a protein called beta-amyloid and tangles of another protein called tau. A paper appearing March 21 in the journal ...

Could drugs used after an organ transplant protect against Alzheimer's?

March 21, 2018
A UT Southwestern study in mice provides new clues about how a class of anti-rejection drugs used after organ transplants may also slow the progression of early-stage Alzheimer's disease.

Cell therapy could improve brain function for Alzheimer's disease

March 15, 2018
Like a great orchestra, your brain relies on the perfect coordination of many elements to function properly. And if one of those elements is out of sync, it affects the entire ensemble. In Alzheimer's disease, for instance, ...

Physically fit women nearly 90 percent less likely to develop dementia

March 14, 2018
Women with high physical fitness at middle age were nearly 90 percent less likely to develop dementia decades later, compared to women who were moderately fit, according to a study published the March 14, 2018, online issue ...

Poor sleep may heighten Alzheimer's risk

March 12, 2018
(HealthDay)—Older adults who are sleepy during the day might have harmful plaque building in their brain that is a sign of impending Alzheimer's disease, researchers report.

Dementia patients with distorted memories may actually retain key information – researchers say

March 7, 2018
Some memories containing inaccurate information can be beneficial to dementia sufferers because it enables them to retain key information researchers say.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.